CIK 0001936258 · Large accelerated filer
NewAmsterdam Pharma Co N.V.
Sign in to watch- Ticker
- NAMS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- Netherlands
- Entity type
- operating
- Phone
- 35 206 2971
- Business address
- GOOIMEER 2-35, NARRDEN, Netherlands, 1411 DC
- Former names
- NewAmsterdam Pharma Co B.V.
Securities
- NAMS Ordinary Shares Nasdaq
- NAMSW Warrant Nasdaq
- Open-market buys, last 90 days
- $226,500
- in 1 filing
- Open-market sales, last 90 days
- $4,661,919
- in 3 filings, $4.6M under 10b5-1 plans
Net −$4,435,419. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-09-30 | Kastelein Johannes Jacob Pieter Chief Scientific Officer | Sale 10b5-1 | −50,246 | $25.03 | $1.3M | 69,302 |
| 2026-09-04 | Smither John W Director | Sale | −1,600 | $25.32 | $41K | 8,760 |
| 2026-08-24 | Kastelein Johannes Jacob Pieter Chief Scientific Officer | Sale 10b5-1 | −125,000 | $26.91 | $3.4M | 69,302 |
| 2026-07-20 | Kooij Louise Frederika Chief Accounting Officer | Sale 10b5-1 | −70,200 | $29.96 | $2.1M | 59,153 |
| 2026-07-20 | Kooij Louise Frederika Chief Accounting Officer | Sale 10b5-1 | −31,885 | $31.05 | $990K | 27,268 |
| 2026-07-20 | Kooij Louise Frederika Chief Accounting Officer | Sale 10b5-1 | −2,915 | $31.71 | $92K | 24,353 |
| 2026-06-22 | Kooij Louise Frederika Chief Accounting Officer | Sale 10b5-1 | −39,700 | $30.20 | $1.2M | 24,653 |
| 2026-06-22 | Kooij Louise Frederika Chief Accounting Officer | Sale 10b5-1 | −300 | $30.73 | $9K | 24,353 |
| 2026-05-26 | Kooij Louise Frederika Chief Accounting Officer | Sale 10b5-1 | −65,000 | $35.69 | $2.3M | 24,353 |
| 2026-03-11 | LANGE LOUIS G Director | Sale | −44,173 | $30.41 | $1.3M | 10,806 |
| 2026-03-11 | LANGE LOUIS G Director | Sale | −446 | $31.23 | $14K | 10,360 |
| 2026-03-09 | Kastelein Johannes Jacob Pieter Chief Scientific Officer | Sale 10b5-1 | −101,409 | $30.29 | $3.1M | 69,302 |
| 2026-03-06 | LANGE LOUIS G Director | Sale | −28,186 | $29.41 | $829K | 0 |
| 2026-03-06 | Kastelein Johannes Jacob Pieter Chief Scientific Officer | Sale 10b5-1 | −94,124 | $30.32 | $2.9M | 69,302 |
| 2026-03-05 | Kastelein Johannes Jacob Pieter Chief Scientific Officer | Sale 10b5-1 | −104,467 | $30.30 | $3.2M | 69,302 |
| 2026-03-02 | Davidson Michael H. Chief Executive Officer | Sale | −443,707 | $33.25 | $14.8M | 174,144 |
| 2026-02-26 | Davidson Michael H. Chief Executive Officer | Sale 10b5-1 | −165,408 | $33.63 | $5.6M | 477,783 |
| 2026-02-26 | Davidson Michael H. Chief Executive Officer | Sale 10b5-1 | −17,924 | $34.44 | $617K | 174,144 |
| 2026-02-25 | Davidson Michael H. Chief Executive Officer | Sale 10b5-1 | −46,517 | $35.11 | $1.6M | 471,595 |
| 2026-02-25 | Davidson Michael H. Chief Executive Officer | Sale 10b5-1 | −10,436 | $35.96 | $375K | 461,159 |
Page 1 of 6 · 102 trades